💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Buformin

CHEMBL39736 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
157.2 g/mol
LogP
-0.6
Phase
4

An older biguanide antidiabetic drug related to metformin, used to treat type 2 diabetes before being withdrawn from most markets due to an unacceptably high risk of lactic acidosis. It lowered blood sugar by reducing glucose production in the liver and improving insulin sensitivity. It is largely of historical interest in the development of diabetes pharmacology.

น้ำหนักโมเลกุล

157.2200 g/mol

LogP

-0.60

TPSA

103.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Lymphoma Type 2 Diabetes

กลไกการออกฤทธิ์

Decreases hepatic glucose production, increases insulin sensitivity in peripheral tissues, and reduces intestinal absorption of glucose. The primary mechanism involves activation of AMP-activated protein kinase (AMPK) in hepatocytes.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Decreases hepatic glucose production, increases insulin sensitivity in peripheral tissues, and reduces intestinal absorption of glucose. The primary mechanism involves activation of AMP-activated protein kinase (AMPK) in hepatocytes.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCNC(=N)NC(=N)N

                

                

                
                

                    
InChI

                    
InChI=1S/C6H15N5/c1-2-3-4-10-6(9)11-5(7)8/h2-4H2,1H3,(H6,7,8,9,10,11)

                

                

                

                    
                    

                        
Molecular Formula

                        
C6H15N5

                    

                    
                    

                        
HBD / HBA

                        
3 / 1

                    

                    
                    

                        
พันธะที่หมุนได้

                        
4

                    

                    
                    
                    

                        
อะตอมหนัก

                        
11

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
An older biguanide antidiabetic drug related to metformin, used to treat type 2 diabetes before being withdrawn from most markets due to an unacceptably high risk of lactic acidosis. It lowered blood sugar by reducing glucose production in the liver and improving insulin sensitivity. It is largely of historical interest in the development of diabetes pharmacology.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Decreases hepatic glucose production, increases insulin sensitivity in peripheral tissues, and reduces intestinal absorption of glucose. The primary mechanism involves activation of AMP-activated protein kinase (AMPK) in hepatocytes.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Buformin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL39736.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 2468.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.